|
Multimodal prediction of response to neoadjuvant nivolumab and chemotherapy for surgically resectable stage IIIA non–small cell lung cancer. |
|
|
Employment - SOPHiA Genetics |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche; Sanofi; Takeda |
Research Funding - Bristol-Myers Squibb (Inst); Merck Serono (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche |
|
|
Employment - SOPHiA Genetics |
Stock and Other Ownership Interests - SOPHiA Genetics |
|
|
No Relationships to Disclose |
|
|
Employment - SOPHiA GENETICS |
Leadership - SOPHiA Genetics |
Stock and Other Ownership Interests - SOPHiA Genetics |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Pfizer; Roche; Takeda |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Merck Serono; Roche; Takeda |
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Roche |
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; MSD Oncology; Pfizer; Roche |
Speakers' Bureau - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche |
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Takeda |
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; MSD Oncology; Novartis; Pfizer; Roche; Sanofi/Aventis; Takeda |
Travel, Accommodations, Expenses - MSD Oncology; Pfizer; Roche/Genentech |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; GlaxoSmithKline; Janssen Oncology; Lilly; Merck Sharp and Dohme; Pfizer; Roche; Sanofi; Takeda |
Travel, Accommodations, Expenses - AstraZeneca Spain; Merck Sharp & Dohme; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Bristol-Myers Squibb/Medarex; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
Employment - SOPHiA Genetics |
Leadership - SOPHiA Genetics |
Stock and Other Ownership Interests - SOPHiA Genetics |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Roche; Takeda |
Speakers' Bureau - AstraZeneca; BMS; MSD; Roche |
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Pierre Fabre (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; BMS; ROCHE |